19 June 2013
Keywords: alexion, completes, enrollment, ph, ii, kidney, disease
Article | 25 February 2002
Alexion has completed enrollment in a Phase II study of its complementC5 inhibitor eculizumab (formerly 5G1.1) in patients with the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
© 2013 thepharmaletter.com